On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

However, for people like Anna Engomba, the arrival of new, life-saving medication ... of the limited available treatment options. While the numbers of people with HIV remains high, treatment ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

The South African National Aids Council is meant to play a co-ordinating role in the country’s response to HIV, bringing ...

Among 198 patients with HIV who received a kidney from a deceased donor, risk of a safety event within a median of 2.2 years was similar between the two groups (adjusted HR 1.00, 95% CI 0.73-1.38), ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

The U.S. Centers for Disease Control and Prevention (CDC) and the President's Emergency Plan for AIDS Relief (PEPFAR), have ...

Persistent failure of HIV treatment was defined as an HIV RNA level ... recurrent events and the proportions of participants with new donor-specific antibodies were quantified with the use of ...